跳至主要内容
临床试验/NCT00635934
NCT00635934已完成不适用

A Prospective, Non-Randomized Pilot Clinical Investigation of the A-MAV™ Anterior Motion Segment Replacement in Patients With Lumbar Degenerative Disc Disease

Medtronic Spinal and Biologics6 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2005年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
53
试验地点
6
主要终点
Overall Success= Oswestry Disability Index success; Maintenance or improvement in neurological status; No serious AE classified as implant or implant/surgical procedure associated; No additional surgical procedure classified as a failure

研究概览

简要总结

The purpose of this clinical trial is to collect safety and effectiveness data concerning the A-MAV™ Anterior Motion Segment Replacement device as a method of treating patients with lumbar degenerative disc disease at one level from L4-S1. Overall success will be the primary clinical endpoint.

详细描述

For this clinical trial, there is only one treatment group- patients receiving the A-MAV™ Anterior Motion Segment Replacement via an anterior surgical approach in the lumbar region of the spine from L4-S1.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Has back and/or radicular pain with degeneration of the disc as confirmed by patient history, physical examination, and radiographic studies with one or more of the following factors:
  • instability as defined by > 5° angulation
  • osteophyte formation of facet joints or vertebral endplates
  • decreased disc height, on average by >2mm, relative to the next adjacent vertebral segment
  • scarring/thickening of ligamentum flavum, annulus fibrosis, or facet joint capsule
  • herniated nucleus pulposus
  • facet joint degeneration/changes
  • vacuum phenomenon
  • Has single-level symptomatic degenerative involvement from L4-S1 requiring surgical treatment
  • Has intact facet joints at the involved vertebral levels documented by CT and/or MRI
  • Has preop Oswestry score≥30
  • Has preop back pain score ≥8
  • Age 18 to 70 yrs, inclusive and is skeletally mature
  • Has not responded to non-operative treatment for 6 mos
  • If child-bearing potential, patient is non-pregnant, non-nursing, and agrees not to become pregnant for 1 yr after surgery
  • Is willing and able to comply with the study plan and sign the Patient Informed Consent Form

排除标准

  • Has primary diagnosis of a spinal disorder other than DDD at involved level
  • Had previous anterior lumbar spinal surgery at involved level
  • Had previous posterior lumbar spinal fusion surgical procedure at involved level
  • Had prior posterior lumbar surgery resulting in significant muscle/ligament morbidity, not including facet saving techniques
  • Requires surgical intervention at more than 1 lumbar level
  • Has severe pathology of facet joints of involved vertebral bodies
  • Has facet arthritis or any posterior element insufficiency
  • Has spondylolisthesis
  • Has mid-sagittal stenosis of <8mm, based on remaining canal diameter
  • Has rotatory scoliosis at involved level
  • Has lumbar scoliosis with >11° sagittal plane deformity
  • Had previous trauma to L4, L5, or S1 levels in compression or burst
  • Meets any of the following criteria: Previous diagnosis of osteoporosis, osteopenia, or osteomalacia; postmenopausal Non-Black female over 60 yrs of age and weighs less than 140 pounds; postmenopausal female that has sustained a non-traumatic hip, spine or wrist fracture; male over age 60 that has sustained a non-traumatic hip or spine fracture. If Yes to any of these, a DEXA scan is required. If level of BMD is -3.5 or lower or -2.5 or lower with vertebral crush fracture, the patient is excluded
  • Had previous lumbar spinal fusion at adjacent level
  • Bone growth stimulator use in spine
  • Has obesity defined by BMI greater than or equal to 40
  • Has arachnoiditis
  • Has a non-contained or extruded herniated nucleus pulposus with acute nerve root compression
  • Has condition that requires postop medications that interfere with bone metabolism, such as chronic steroid use or prolonged use of non-steroidal anti-inflammatory drugs, excluding routine perioperative, non-steroidal anti-inflammatory drugs. Does not include low dose aspirin for prophylactic anticoagulation
  • Has overt or active bacterial infection, either local or systemic and/or potential for bacteremia
  • Has presence or prior history of malignancy (except for basal cell carcinoma of skin)
  • Has documented metal allergy, titanium alloy intolerance or cobalt-chrome-molybdenum alloy
  • Is mentally incompetent. If questionable, obtain psych consult
  • Has a Waddell Signs of Inorganic Behavior score of 3 or greater
  • Has chronic or acute renal and/or hepatic failure or prior history of renal and/or hepatic parenchymal disease
  • Is prisoner
  • Is pregnant
  • Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug abuse
  • Has history of autoimmune disease
  • Has received treatment with an investigational therapy within 30 days prior to implantation surgery or treatment is planned during 24 months following the implantation surgery
  • Has history of any endocrine or metabolic disorder known to affect osteogenesis
  • Has any disease that would preclude accurate clinical evaluation

研究组 & 干预措施

A-MAV™disc

Experimental

干预措施: A-MAV™ disc (Device)

结局指标

主要结局

Overall Success= Oswestry Disability Index success; Maintenance or improvement in neurological status; No serious AE classified as implant or implant/surgical procedure associated; No additional surgical procedure classified as a failure

时间窗: 24 Months

次要结局

  • Disc height; SF-36; Back Pain Status; Leg Pain Status; Patient Satisfaction; Patient Global Perceived Effect; Other Measurements-Radiographic; Return to Work; Doctor's Perception of Results(24 Months)

研究者

发起方
Medtronic Spinal and Biologics
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验